A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin

In conclusion, dapagliflozin does not act as promoter or progressor of bladder cancer in a validated bladder cancer model in rats.
Source: Regulatory Toxicology and Pharmacology - Category: Toxicology Source Type: research